Table 3.
JSCCR | NCCN | ESMO |
---|---|---|
UFT+LV | FOLFOX | FOLFOX |
Cape | CapeOX | CapeOX |
S‐1 | FLOX | Cape |
5‐FU+l‐LV | Cape | 5‐FU+l‐LV |
FOLFOX | 5‐FU+l‐LV | |
CapeOX |
Cape, capecitabine; CapeOX, capecitabine+oxaliplatin; ESMO, European Society for Medical Oncology; FLOX, infusional fluorouracil+l‐leucovorin (weekly)+oxaliplatin (biweekly); FOLFOX, infusional fluorouracil+l‐leucovorin+oxaliplatin; 5‐FU+l‐LV, fluorouracil+l‐leucovorin; JSCCR, Japanese Society for Cancer of the Colon and Rectum; NCCN, National Comprehensive Cancer Network; S‐1, tegafur‐gimeracil‐oteracil potassium; UFT+LV, tegafur‐uracil+leucovorin.